Home / Healthcare/ AstraZeneca’s key lung cancer drug wins European panel thumbs-up

AstraZeneca’s key lung cancer drug wins European panel thumbs-up


Comments / {{hitsCtrl.values.hits}} Views / Tuesday, 31 July 2018 00:00

Facebook

Reuters: AstraZeneca’s cancer drug Imfinzi has won a key recommendation from a European Medicines Agency (EMA) panel less than six months after the first global approvals in Western markets.

EMA’s Committee for Medicinal Products for Human Use (CHMP) recommended Imfinzi, an immunotherapy drug already boosting sales for the British drugmaker, for use in lung cancer patients with inoperable disease that had advanced locally but not spread widely around the body.

While final approvals are up to the European Commission, it generally follows the CHMP’s recommendation and endorses them within a couple of months.

The US Food and Drug Administration (FDA) in February granted approval for expanded use of Imfinzi to treat non-small cell lung cancer (NSCLC) patients with inoperable mid-stage disease that has not spread widely around the body.

Japan also approved the drug earlier this month.

The latest green light - which had been expected after positive clinical data last year - gives AstraZeneca a chance to intervene earlier in lung cancer, distinguishing it from rivals that have approval for tackling advanced or metastatic disease.

Globally, about 30% of patients with NSCLC present with stage III disease. These individuals typically receive a combination of chemotherapy and radiotherapy, but only around 15% of them are still alive after five years.

Imfinzi, chemically known as durvalumab, belongs to a new class of immuno-oncology drugs that block a mechanism tumors use to evade detection from the immune system.

AstraZeneca’s drug already had approval for treating certain patients with bladder cancer. However, this market is relatively small.

The really big opportunity for all companies seeking to exploit the power of modern immuno-oncology drugs is lung cancer, since it is the leading cause of cancer deaths.

Bristol-Myers Squibb, Roche and Merck all have approved products for treating certain patients with advanced lung cancer - but AstraZeneca is now in a position to carve out a niche in treating earlier stage III patients.


Share This Article

Facebook Twitter


DISCLAIMER:

1. All comments will be moderated by the Daily FT Web Editor.

2. Comments that are abusive, obscene, incendiary, defamatory or irrelevant will not be published.

3. We may remove hyperlinks within comments.

4. Kindly use a genuine email ID and provide your name.

5. Spamming the comments section under different user names may result in being blacklisted.

COMMENTS

Today's Columnists

Timely measures are necessary to save the local industries

Thursday, 20 June 2019

The security situation in the country is gradually improving since the Easter Sunday bombing which brought social life and economic commitments to a standstill. The day-to-day life is getting back to normalcy. International travel adversaries have be


Disinformation is bad; wilful disinformation is worse

Thursday, 20 June 2019

Seya Sadewmi was a five-year-old girl who was abducted, raped and murdered. The body of this little girl, missing from her home for a little more than a day was found near a canal 200 m away. An autopsy revealed that Sadewmi had been sexually assault


A day in the life of a democracy

Thursday, 20 June 2019

When you listen to the news and observe views from the country of the mother of all parliaments, it is quite interesting, and I dare say there is so much to learn from it. I am not in any way referring to pursue subservient veneration nor behavioural


Sri Lankan companies: Be brilliant on basics

Thursday, 20 June 2019

The $ 87 billion Sri Lanka economy is registered a 3.5% GDP growth in Q1 2019 in the backdrop of South Asian growing at 6% which explains how far away we are in relation to our neighbouring countries – India, Pakistan and Bangladesh. I guess the Q2


Columnists More